Cardiovascular medicine in China: what can we do to achieve the Healthy China 2030 plan?

被引：20
作者：
Bei, Yihua [1 ]
Yang, Tingting [1 ]
Xiao, Junjie [1 ]
机构：
[1] Shanghai Univ, Inst Cardiovasc Sci, 381 Nan Chen Rd, Shanghai 200444, Peoples R China
来源：
BMC MEDICINE | 2018年 / 16卷
基金：
中国国家自然科学基金;
关键词：
Cardiovascular diseases; China; Healthy China 2030; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; OUTCOMES; TRIAL; EFFICACY; SAFETY; STENTS;
D O I：
10.1186/s12916-018-1133-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cardiovascular diseases (CVDs) represent the leading cause of death in China. The Chinese government approved the Healthy China 2030 plan (jiankang zhongguo 2030), emphasizing the strategic role of health in China's development. As morbidity and mortality from CVDs are constantly increasing in China, the prevention and treatment of CVDs are vital to achieve this plan. Following the major principles of health priority, science and technology innovation, scientific development, and balanced medical resource allocation outlined in the Healthy China 2030 plan, this Commentary briefly introduces the current status of CVDs in China and marks the important events undertaken to achieve this plan.
引用
收藏
页数：3
相关论文
共 113 条
  • [1] Chen W(2018)Summary of the report on cardiovascular diseases in China (2017) Chin Circ J 33 1-8
  • [2] Gao R(2015)Current aging research in China Protein Cell 6 314-321
  • [3] Liu L(2017)Overweight, obesity, and screen-time viewing among Chinese school-aged children: national prevalence estimates from the 2016 physical activity and fitness in China—the youth study J Sport Health Sci 6 404-409
  • [4] Zhu M(2010)Global estimates of ambient fine particulate matter concentrations from satellite-based aerosol optical depth: development and application Environ Health Perspect 118 847-855
  • [5] Wang W(2015)Relationship between fine particulate air pollution and ischaemic heart disease morbidity and mortality Heart 101 257-263
  • [6] Wang Y(2015)Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial JAMA 313 1336-1346
  • [7] Wu Z(2009)Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in “real-world” practice: 18-month clinical and 9-month angiographic outcomes JACC Cardiovasc Interv 2 303-309
  • [8] Li H(2016)Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer Sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial Circ Cardiovasc Interv 9 733-739
  • [9] Gu D(2009)Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2298-2309
  • [10] Yang Y(2015)Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial J Am Coll Cardiol 66 1462-1473
12345678910